Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 6/20 | 0.54 |
| ▸ | ACHE | P22303 | 6/20 | 0.54 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.47 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.47 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 12/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 10/20 | 0.44 |
| ▸ | SIRT3 | Q9NTG7 | 7/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4386983 | 1.00 | BCHE (0.54) | BCHEACHECACNA1FCACNA1DCACNA1S | |
| SCHEMBL13671075 | 1.00 | BCHE (0.54) | BCHEACHECACNA1FCACNA1DCACNA1S | |
| SCHEMBL757489 | 0.81 | SIRT2 (0.44) | BCHEACHESIRT2SIRT1SIRT3 | |
| SCHEMBL14509601 | 0.79 | GNAI3 (0.42) | BCHEACHECACNA1FCACNA1DCACNA1S | |
| SCHEMBL13671064 | 0.75 | GNAI3 (0.41) | BCHEACHECACNA1FCACNA1DCACNA1S | |
| SCHEMBL13671074 | 0.72 | CTSS (0.50) | SIRT2CTSLCTSS | |
| SCHEMBL757049 | 0.72 | CTSS (0.50) | SIRT2CTSLCTSS | |
| SCHEMBL13465369 | 0.72 | GNAI3 (0.54) | BCHEACHEITGB3ITGA2B | |
| SCHEMBL2118680 | 0.71 | CTSL (0.77) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL12109633 | 0.71 | CTSL (0.59) | SIRT2SIRT1SIRT3CTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2842576-B1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK HEALTHCARE AG (CH) | 2017-06-28 | — | — | EP | disclosed |
| EP-2842576-A1 | Transglutaminase mediated conjugation of peptides | Novo Nordisk Health Care AG (CH) | 2015-03-04 | — | — | EP | disclosed |
| EP-2033662-B1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK HEALTHCARE AG (CH) | 2012-10-17 | — | — | EP | disclosed |
| EP-1708755-B1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK HEALTHCARE AG (CH) | 2012-03-21 | — | — | EP | disclosed |
| US-20090264366-A1 | Transglutaminase Mediated Conjugation of Peptides | NOVO NORDISK HEALTHCARE AG (CH) | 2009-10-22 | — | — | US | disclosed |
| EP-2033662-A1 | Transglutaminase mediated conjugation of peptides | Novo Nordisk Health Care AG (CH) | 2009-03-11 | — | — | EP | disclosed |
| US-20070105770-A1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-10 | — | — | US | disclosed |
| EP-1708755-A2 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005070468-A2 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264366-A1 | Transglutaminase Mediated Conjugation of Peptides | TGM2, TGM3, TGM1 | BCHE 192/4885ACHE 846/4885CACNA1F 4828/4885 |
| US-20070105770-A1 | Transglutaminase mediated conjugation of peptides | TGM2, TGM3, TGM1 | BCHE 192/4885ACHE 846/4885CACNA1F 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.